Babesiosis is a zoonotic disease transmitted by Ixodes ticks seen in the United States and parts of Europe. Because of the typically mild course of most infections, the disease is uncommonly seen in clinical practice. However, asplenic patients can develop a life-threatening infection. The first line of therapy for infections is antiparasitic medications; however, red blood cell (RBC) exchange transfusion has been described as an adjunct therapy. We describe a severe case of babesiosis in an asplenic patient and review the evidence, indications, and protocols for RBC exchange transfusion in this setting.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5144532 | PMC |
| http://dx.doi.org/10.4103/0972-5229.194017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Approach to autologous stem cell transplantation in a patient with severe cold agglutinin disease, a case report.
Transfusion
January 2025
Hematology-Oncology and Cell Therapy University Institute, Hôpital Maisonneuve-Rosemont Research Center, Montréal, Quebec, Canada.
Background: Cold agglutinin disease (CAD) or syndrome (CAS) can be particularly challenging when autologous stem cell transplant (ASCT) is needed. Standard peripheral blood stem cell (PBSC) collection and manipulation involve ex vivo blood manipulations at lower than body temperature, predisposing to agglutination during graft collection, handling, processing, and infusion.
Study Design And Methods: We describe the first case of ASCT for relapsing lymphoma in a patient with high-titer CAD requiring anti-complement therapy and chronic transfusion.
Background: Babesiosis poses significant risks of adverse outcomes in individuals with immunocompromising conditions (IC) and asplenia/hyposplenia (AH). This study compares clinical outcomes between these vulnerable groups and immunocompetent patients.
Methods: A multicenter retrospective cohort study included adult patients with laboratory-confirmed babesiosis from 2009 to 2023.
Strengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania.
BMJ Glob Health
January 2025
Sickle Cell Programme, Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps remain in advanced treatments for SCD. To help address this burden, Tanzania has established one of the largest single-centre SCD programmes in the world and developed an advanced therapy programme for SCD focused on patient engagement and advocacy, clinical activities involving exchange blood transfusion (ExBT) and haematopoietic stem cell transplant (HSCT), gene therapy (GT) preparedness, and enabling partnerships. This report describes the programme's genesis, structure and progress achieved.
View Article and Find Full Text PDFResearch on blood donation and supply of red blood cell products to medical institutions under the spread of COVID-19 disease in Japan.
Heliyon
January 2025
Cooperative Major in Advanced Biomedical Sciences of Tokyo Women's Medical University and Waseda University, 2-2, TWIns, Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, Japan.
Due to the spread of SARS-CoV-2 virus infectious disease (COVID-19), blood donation events had to be cancelled, and there were concerns about a decrease in the number of blood donors from late February 2020 in Japan. The purpose of this study is to investigate the numbers of whole blood donation, manufacture and inventory adjustment of red blood cell (RBC) products at the Japanese Red Cross Society (JRCS), and to evaluate the effects of COVID-19 on the donation of blood and the supply of RBC products to medical institutions for transfusion medicine in Japan. We focused on RBC products, which are the most frequently used blood products and are easily reflected under the spread of COVID-19.
View Article and Find Full Text PDFRed blood cell utilization in patients with sickle cell disease: A Canadian single-center experience.
Transfusion
January 2025
Ottawa Hospital Research Institute, Ottawa Hospital Center for Transfusion, Ottawa, Ontario, Canada.
Background: Red blood cell (RBC) utilization in patients with sickle cell disease (SCD) in Canada is poorly defined. This study describes RBC utilization in an SCD cohort at a single Canadian center.
Study Design And Methods: All adults with SCD who received care at the Ottawa Hospital between January 2006 and May 2019 were included, and followed until December 2021.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!